Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Chinese Journal of Hepatology ; (12): 428-432, 2023.
Article in Chinese | WPRIM | ID: wpr-986147

ABSTRACT

Objective: Glycogen storage disease type IX (GSD-IX) is a rare primary glucose metabolism abnormality caused by phosphorylase kinase deficiency and a series of pathogenic gene mutations. The clinical characteristics, gene analysis, and functional verification of a mutation in a child with hepatomegaly are summarized here to clarify the pathogenic cause of the disease. Methods: The clinical data of a child with GSD-IX was collected. Peripheral blood from the child and his parents was collected for genomic DNA extraction. The patient's gene diagnosis was performed by second-generation sequencing. The suspected mutations were verified by Sanger sequencing and bioinformatics analysis. The suspected splicing mutations were verified in vivo by RT-PCR and first-generation sequencing. Results: Hepatomegaly, transaminitis, and hypertriglyceridemia were present in children. Liver biopsy pathological examination results indicated glycogen storage disease. Gene sequencing revealed that the child had a c.285 + 2_285 + 5delTAGG hemizygous mutation in the PHKA2 gene. Sanger sequencing verification showed that the mother of the child was heterozygous and the father of the child was of the wild type. Software such as HSF3.1 and ESEfinder predicted that the gene mutation affected splicing. RT-PCR of peripheral blood from children and his mother confirmed that the mutation had caused the skipping of exon 3 during the constitutive splicing of the PHKA2 gene. Conclusion: The hemizygous mutation in the PHKA2 gene (c.285 + 2_285 + 5delTAGG) is the pathogenic cause of the patient's disease. The detection of the novel mutation site enriches the mutation spectrum of the PHKA2 gene and serves as a basis for the family's genetic counseling.


Subject(s)
Child , Humans , Male , Female , Exons , Glycogen Storage Disease/genetics , Hepatomegaly/genetics , Mutation , Phosphorylase Kinase/genetics
2.
Pediatric Gastroenterology, Hepatology & Nutrition ; : 138-143, 2015.
Article in English | WPRIM | ID: wpr-72729

ABSTRACT

Glycogen storage disease type IX (GSD IX) is caused by a defect in phosphorylase b kinase (PhK) that results from mutations in the PHKA2, PHKB, and PHKG2 genes. Patients usually manifest recurrent ketotic hypoglycemia with growth delay, but some may present simple hepatomegaly. Although GSD IX is one of the most common causes of GSDs, its biochemical and genetic diagnosis has been problematic due to its rarity, phenotypic overlap with other types of GSDs, and genetic heterogeneities. In our report, a 22-month-old boy with GSD IX is described. No other manifestations were evident except for hepatomegaly. His growth and development also have been proceeding normally. Diagnosed was made by histologic examination, an enzyme assay, and genetic testing with known c.3210_3212del (p.Arg1070del) mutation in PHKA2 gene.


Subject(s)
Child , Humans , Infant , Male , Diagnosis , Enzyme Assays , Genetic Heterogeneity , Genetic Testing , Glycogen Storage Disease , Glycogen , Growth and Development , Hepatomegaly , Hypoglycemia , Phosphorylase Kinase
3.
Rev. bras. anal. clin ; 34(1): 15-20, 2002. tab
Article in Portuguese | LILACS | ID: lil-519735

ABSTRACT

A enzima fosforilase b-quinase catalisa a fosforilação da fosforilase (b), inativa, em fosforilase (a), ativa. A sua deficiência provoca a glicogenose tipo IX. Neste trabalho é desenvolvido um método para a determinação da atividade da fosforilase b-quinase em hemácias possibilitando o diagnóstico laboratorial desta doença de estocagem de glicogênio.


Subject(s)
Humans , Erythrocytes , Glycogen Storage Disease , Phosphorylase b , Phosphorylase Kinase
4.
Acta bioquím. clín. latinoam ; 33(1): 35-47, mar. 1999. ilus
Article in Spanish | LILACS | ID: lil-241827

ABSTRACT

Cuando un agonista se une a su receptor específico sobre la membrana plaquetaria se inician una serie de cambios morfológicosy metabólicos que llevan al cambio de forma, agregación y secreción de contenidos granulares. La trombina, serinoproteasa multifuncional y fuerte agonosta plaquetario, tiene dos tipos de receptores sobre la membrana plaquetaria: de alta y de moderada afinidad. Este último pertenece a la familia de receptores ß2 adrenérgicos que presentan siete dominios de intramembrana, e inician la activación a través de G proteínas específicas. De esta manera se desencadenan diversos pasos metabólicos a través de varias enzimas claves. La actividad de la fosfolipasa Cß (PLCß) origina dos segundos mensajeros: Inositol 3 fosfato (IP3) que promueve la movilización de calcio del sistema tubular denso al citosol y el diacilglicerol (DG) que activa proteína quinasa C (PKC). Si bien la plaqueta no prolifera se han detectado enzimas relacionadas a oncogenes. De esta manera se han estudiado y comprendido nuevos caminos de activación. La familia de la tirosina quinasas, relacionas a la proliferación celular y oncogenes, fosforilan residuos tirosinas; en su mayoría son quinasas del tipo no receptor que se encuentran en el citosol como ser: Scr, Syk y FAK. La fosfolipasa Cy necesita la presencia de RasGAP, Rap 1b para hidrolizar fosfoinosítidos de membrana. La formación de este complejo trimérico se induce por trombina. La fosfoinositol-3-quinasa fosforila la posición 3 del anillo del inositol generando nuevos compuestos. La regulación completa de estos mecanismos de activación llevan a la respuesta hemostática plaquetaria. Su conocimiento hace posible el desarrollo de moléculas inhibitorias como terapéutica en los procesos trombóticos y tromboembólicos


Subject(s)
Humans , Platelet Activation , Antibodies, Monoclonal/therapeutic use , In Vitro Techniques , Receptors, Thrombin/drug effects , Thrombin/physiology , Thrombosis/physiopathology , Platelet Activation/physiology , Platelet Aggregation , Antibodies/therapeutic use , Blood Platelets/drug effects , Blood Coagulation/physiology , Phosphatidylinositols/metabolism , Phosphatidylinositols/physiology , Phosphorylase Kinase , Receptors, Thrombin/antagonists & inhibitors , Receptors, Thrombin/classification , Second Messenger Systems , Thrombin/chemistry , Thrombosis/drug therapy , Thrombosis/therapy
SELECTION OF CITATIONS
SEARCH DETAIL